grant

Optimizing immunoradiotherapy for HNSCC

Organization UNIVERSITY OF CALIFORNIA, SAN DIEGOLocation LA JOLLA, UNITED STATESPosted 25 Sept 2023Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY2025AblationAbscissionAbsolute ethanolAgonistAnimal ModelAnimal Models and Related StudiesAnti-CD47Antigen PresentationAntigen-Presenting CellsAntitumor ResponseArchitectureB blood cellsB cellB cellsB-CellsB-LymphocytesB-cellCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCD47CD47 AntigenCD47 GlycoproteinCD47 geneCD8CD8BCD8B1CD8B1 geneCancer Causing AgentsCancersCarcinogensCell BodyCell Communication and SignalingCell SignalingCellsCheckpoint inhibitorClinicalClinical DataClinical TrialsDataDeath RateDendritic CellsETOHEatingEngineering / ArchitectureEthanolEthyl AlcoholExcisionExtirpationFood IntakeGrain AlcoholHNC patientHNSCCHPVHPV(-) HNSCCHPV(-) head and neck squamous cell carcinomaHPV- HNSCCHPV-negative HNSCCHPV-negative head and neck cancerHPV-negative head and neck squamous cell carcinomaHead and Neck CancerHead and Neck CarcinomaHead and Neck Squamous Cell CarcinomaHuman Papilloma VirusHuman PapillomavirusImmuneImmune SurveillanceImmune checkpoint inhibitorImmune mediated therapyImmune responseImmunesImmunochemical ImmunologicImmunologicImmunologic SurveillanceImmunologicalImmunologicallyImmunologically Directed TherapyImmunologicsImmunoradiotherapyImmunosurveillanceImmunotherapyIn complete remissionInduction TherapyInfectious Human Wart VirusIntegrin-Associated ProteinIntracellular Communication and SignalingInvestigationLYT3Localized DiseaseLymph Node Reticuloendothelial SystemLymph node properLymphaticLymphatic nodesMER6Malignant Head and Neck NeoplasmMalignant NeoplasmsMalignant TumorMetastatic/RecurrentMethylcarbinolModelingMorbidityMorbidity - disease rateNEOADJNeoadjuvantNeoadjuvant TherapyNeoadjuvant TreatmentNivolumabNodalOncogenicOncogensOpdivoOperative ProceduresOperative Surgical ProceduresOutcomePD 1PD-1PD1PathologicPatientsPhagocytosisPhasePhenotypePrimary NeoplasmPrimary TumorRadiationRadiation therapyRadioimmunotherapyRadiotherapeuticsRadiotherapyRegional DiseaseRemovalResearchRoleSCCHNSentinel Lymph NodeSentinel NodeSignal TransductionSignal Transduction SystemsSignalingSolid NeoplasmSolid TumorSurface Antigen Identified by Monoclonal Antibody 1D8SurgicalSurgical InterventionsSurgical ProcedureSurgical RemovalT cell clonalityT-Cell ActivationT-CellsT-LymphocyteT-cell receptor clonalityT4 CellsT4 LymphocytesTCR clonalityTLR proteinTeff cellTherapeuticTobaccoToll-Like Receptor Family GeneToll-like receptorsTreatment-related toxicityTumor AntigensTumor CellTumor ImmunityTumor-Associated AntigenVeiled Cellsaccessory cellactivate T cellsanti-canceranti-cancer immunotherapyanti-tumor immune responseanti-tumor immunityanti-tumor responseanticancer immunotherapyantitumor immunitybiological signal transductioncancer antigenscancer immunitycancer immunotherapycell typechemo-/radio-therapychemo-radiotherapychemoradiationchemoradiation therapychemoradiation treatmentchemoradiotherapychemotherapycombinatorialcomplete responseconventional therapyconventional treatmentcurative interventioncurative therapeuticcurative therapycurative treatmentscytokinecytotoxicdesigndesigningdraining lymph nodeeffector T cellhead and neck cancer patienthead and neck squamous carcinomahead and neck squamous cell cancerhead/neck cancerhost responsehuman papillomavirus (-) head and neck squamous cell carcinomahuman papillomavirus - head and neck squamous cell carcinomahuman papillomavirus negative head and neck cancerhuman papillomavirus negative head and neck squamous cell carcinomahuman papillomavirus- head and neck squamous cell carcinomaimmune check point inhibitorimmune microenvironmentimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based cancer therapiesimmune-based therapiesimmune-based treatmentsimmuno therapyimmunoresponseimmunosuppressive microenvironmentimmunosuppressive tumor microenvironmentimmunotherapy for cancerimmunotherapy of cancerimprovedimproved outcomeinduction therapiesinhibitorinsightirradiationlymph channellymph glandlymph nodeslymph vessellymphatic channellymphatic vessellymphnodesmalignancymalignant head and neck tumormodel of animalmortality ratemortality ratiomouse modelmurine modelneoplasm/cancerneoplastic cellnon-HPV HNSCCnon-human papillomavirus head and neck squamous cell carcinomanoveloncogenic agentphase 1 trialphase 3 trialphase I trialphase III trialpreservationprogrammed cell death 1programmed cell death protein 1programmed death 1radiation treatmentradio-chemo-therapyradio-chemotherapyradiochemotherapyregional lymph noderesectionresponsesle2social rolesurgerysystemic lupus erythematosus susceptibility 2therapeutic toxicitytherapy associated toxicitytherapy optimizationtherapy related toxicitytherapy toxicitythymus derived lymphocytetraffickingtreatment optimizationtreatment toxicitytreatment with radiationtreatment-associated toxicitytumortumor immune microenvironmenttumor-immune system interactionstumor-specific antigenwart virus
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

Project Summary
Head and neck squamous cell carcinoma (HNSCC) is driven by tobacco, ethanol and other carcinogens as well

as oncogenic human papilloma virus (HPV). In particular, HPV negative HNSCC has a high rate of mortality and

the main curative treatment options for local and regional disease, including surgery, radiation, and

chemotherapy,…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →
Optimizing immunoradiotherapy for HNSCC — UNIVERSITY OF CALIFORNIA, SAN DIEGO | UNITED STATES | Sept 2023 | Dev Procure